AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Foghorn Therapeutics to Present at Four Conferences in May.
ByAinvest
Thursday, May 22, 2025 7:06 am ET1min read
Foghorn Therapeutics, a clinical-stage biotech company, announced that management will participate in various upcoming conferences. These include the Evercore Biotech Diamonds in the Rough Virtual Event, TD Cowen's 6th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference 2025, and Goldman Sachs 46th Annual Global Healthcare Conference 2025. The company's focus is on oncology, with the potential to transform lives through its Gene Traffic Control platform and broad pipeline.
Cambridge, Mass., May 22, 2025 (GLOBE NEWSWIRE) — Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company specializing in gene expression correction, has announced its participation in several upcoming investor conferences. The company's management, led by President and CEO Adrian Gottschalk, will present at the Evercore Biotech Diamonds in the Rough Virtual Event, TD Cowen’s 6th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference 2025, and Goldman Sachs 46th Annual Global Healthcare Conference 2025.The Evercore Biotech Diamonds in the Rough Virtual Event will feature a fireside chat with Adrian Gottschalk on May 27, 2025, at 2:00 p.m. EDT [1]. The TD Cowen’s 6th Annual Oncology Innovation Summit will also host a fireside chat with Gottschalk on May 28, 2025, at 1:30 p.m. EDT. The Jefferies Global Healthcare Conference 2025, taking place in New York on June 5, 2025, at 3:45 p.m. EDT, will include a presentation by Gottschalk. Additionally, the Goldman Sachs 46th Annual Global Healthcare Conference 2025, scheduled for June 11, 2025, at 10:00 a.m. EDT in Miami, will feature a presentation by Gottschalk.
Foghorn Therapeutics focuses on oncology, leveraging its proprietary Gene Traffic Control® platform to develop a broad pipeline of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company aims to transform the lives of people suffering from a wide spectrum of diseases.
For more information on Foghorn Therapeutics and its upcoming events, please visit their website at www.foghorntx.com [2].
References:
[1] https://www.marketscreener.com/quote/stock/FOGHORN-THERAPEUTICS-INC-114282635/news/Foghorn-Therapeutics-to-Participate-in-Four-Upcoming-Investor-Conferences-50037145/
[2] https://www.foghorntx.com
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet